XML 47 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
 9 Months Ended
Mar. 31, 2017
Segment Reporting [Abstract]  
Net Revenue and Segment EBITDA
The following tables include net revenue and Segment EBITDA during the three and nine months ended March 31, 2017 and March 31, 2016:
 
Three Months Ended  
 March 31,
 
Nine Months Ended  
 March 31,
(Dollars in millions)
2017
 
2016
 
2017
 
2016
Softgel Technologies
 
 
 
 
 
 
 
Net revenue
$
209.9

 
$
185.1

 
$
598.2

 
$
550.2

Segment EBITDA
51.4

 
35.4

 
125.3

 
104.8

Drug Delivery Solutions
 
 
 
 
 
 
 
Net revenue
234.6

 
190.5

 
639.9

 
568.2

Segment EBITDA
59.5

 
39.9

 
151.5

 
139.5

Clinical Supply Services
 
 
 
 
 
 
 
Net revenue
97.5

 
71.5

 
249.5

 
226.0

Segment EBITDA
15.7

 
12.1

 
37.8

 
39.5

Inter-segment revenue elimination
(9.4
)
 
(9.1
)
 
(29.1
)
 
(28.5
)
Unallocated Costs (1)
(32.8
)
 
(17.1
)
 
(72.9
)
 
(43.9
)
Combined Totals:
 
 
 
 
 
 
 
Net revenue
$
532.6

 
$
438.0

 
$
1,458.5

 
$
1,315.9

 
 
 
 
 
 
 
 
EBITDA from continuing operations
$
93.8

 
$
70.3

 
$
241.7

 
$
239.9


(1)
Unallocated costs includes equity-based compensation, certain acquisition-related costs, impairment charges, certain other corporate directed costs, certain customer claim expenses related to the Beinheim facility suspension and other costs that are not allocated to the segments as follows:
 
Three Months Ended  
 March 31,
 
Nine Months Ended  
 March 31,
(Dollars in millions)
2017
 
2016
 
2017
 
2016
Impairment charges and gain/(loss) on sale of assets
$
(1.8
)
 
$
0.3

 
$
(2.3
)
 
$
(0.8
)
Equity compensation
(4.6
)
 
(3.6
)
 
(16.4
)
 
(8.7
)
Restructuring and other special items (2)
(8.5
)
 
(9.5
)
 
(21.6
)
 
(15.7
)
Noncontrolling interest
—

 
—

 
—

 
0.3

Other income/(expense), net (3)
(7.3
)
 
4.2

 
(3.4
)
 
7.1

Non-allocated corporate costs, net
(10.6
)
 
(8.5
)
 
(29.2
)
 
(26.1
)
Total unallocated costs
$
(32.8
)
 
$
(17.1
)
 
$
(72.9
)
 
$
(43.9
)


(2)
Segment results do not include restructuring and other costs associated with certain customer claim expenses related to the Beinheim facility suspension and certain acquisition-related costs.
(3)
Amounts primarily relate to foreign currency translation gains and losses during all periods presented.
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA
Provided below is a reconciliation of EBITDA from continuing operations to earnings/(loss) from continuing operations, the closest related measure prepared in accordance with GAAP:
 
Three Months Ended  
 March 31,
 
Nine Months Ended  
 March 31,
(Dollars in millions)
2017
 
2016
 
2017
 
2016
Earnings from continuing operations
$
26.0

 
$
10.7

 
$
48.0

 
$
53.1

Depreciation and amortization
36.5

 
34.8

 
107.8

 
105.5

Interest expense, net
22.6

 
21.7

 
67.5

 
66.7

Income tax (benefit)/expense
8.7

 
3.1

 
18.4

 
14.3

Noncontrolling interest
—

 
—

 
—

 
0.3

EBITDA from continuing operations
$
93.8

 
$
70.3

 
$
241.7

 
$
239.9
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements: 
(Dollars in millions)
March 31, 
 2017
 
June 30, 
 2016
Assets
 
 
 
Softgel Technologies
$
1,590.7

 
$
1,446.4

Drug Delivery Solutions
1,560.7

 
1,475.7

Clinical Supply Services
595.4

 
578.9

Corporate and eliminations
(461.6
)
 
(409.9
)
Total assets
$
3,285.2

 
$
3,091.1